Get started

Nektar

Nektar Therapeutics (NASDAQ: $NKTR) Ready To Kick Cancer's Azz🦵Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.
NASDAQ:NKTRLong
by RedHotStocks
2
Nektar is reaching fair valueNektar and Bristol-Myers Squibb announced today the companies have agreed to a new joint development plan to advance bempegaldesleukin (bempeg) plus Opdivo (nivolumab) into multiple new registrational trials (source: Yahoo Finance). The 19% jump is making Nektar trading around its fair value. Likely, profit-taking will take place in the next sessions. I'm expecting the stock price to consolidate around $23 level. Disclosure: My ideas contain statements and projections based on assumptions on capital markets, and therefore inherently subject to numerous risks and uncertainties. Before buying or selling any stock you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal. I am not a financial advisor. Don't forget to support this idea, if you liked it, and to follow me here on TradingView. Investing Fellow
NASDAQ:NKTR
by Investing_Fellow
1
Historical Chart; Picking numbers in the range for 3/2020 In my previous idea dated 12/21/2018, "NKTR SHORT 1-Year, Historical supports show more downside.", I pegged a bottom support at $16. (I realize it dropped slightly below that last month). On 12/26/2018, I updated the idea to give a range for 12/31/2019, "Bullish/Bearish Outlook Dec 30th, 2019", pegging a Bearish sentiment at ~$16.32 and Bullish sentiment at ~$36.19 for 12/31/2019. (Within range) I listen to the Earnings Calls, although, I admit, I am at a loss with most of the terminology and technology. This week's call v. last quarter's was a huge difference in the overall sentiment coming from CEO Howard Robin. In this call, Mr. Robin, along with all others on the call, had an encouraging vibe, with positive R&D updates, increased Phase developments within their pipeline, and as mentioned earlier in the week, regulatory committees picking up the review of NKTR 181 (www.nektar.com), to be reviewed in "the next few months". This morning I am taking a wide shot look at Nektar's history, and preparing ranges for where the stock may go from here: Bearish sentiment supports: ~$13.42 ~$16.33 Bullish sentiment supports: ~$20.47 ~$25.29 (7-day moving average) ~$27.99 ~$32.57 ~$44.82 (29-day moving average) Please leave a comment, idea, constructive criticism, question, or hilarious joke to help with my growth and education. I am NOT a financial advisor, CPA, or any other sort of person you should "Take to the Bank." Do your own research. God gave you a mind of your own, use it. I am an individual investor with three NKTR options (1 Sell at $75/sh, 2 Buys at $8 and $20) contracts expiring 1/17/2019 and 21 shares ($17.98/avg cost), at this time. I share my ideas on Tradingview to lockdown my own thoughts on the product and have to look back on. If my ideas help you, GREAT!! If not, oops. Happy hunting.
NASDAQ:NKTRLong
by QUINNsNextStep
2
No jump before earnings; Drop to $30? $25? $20? $Sideways? Can't get back above 0 on MACD. Can't get back above 50 on Stoch RSI. TradingNewsNow claims an intrinsic value per share above $130. Results and Presentations seem to not be helping. I'd "like" to see $41/share, but $24/share might be more the direction of Nektar Therapeutics before a rebound. Continuing to watch sideways movements between $30-$37 in the meantime. Not a broker, nor is this financial advice. I had Nektar hope in opioid replacements for pain therapy and immuno-oncology therapies. I guess they simply cannot beat cannabis in providing quality of life.
NASDAQ:NKTR
by QUINNsNextStep
NKTR Short-term downside?: More Patterns for considerationMy chart is getting a bit messy, however, this one does shoe a consistent pattern on both MACD and Stochastic RSI, making this either the BEST time to BUY, or the WORST time to BUY. It may break $50/share by the end of summer, and End of February Earnings could rebound the stock up to $70+ on the Bullish Side over 3-6 months. On the Bearish side, I am still looking at previous numbers $25-$37/share before any additional rebound. Again, barring any medical breakthroughs. NOT FINANCIAL ADVICE. Let me know what you think of my ideas, any counter reasoning, or other pertinent/interesting information pertaining to Nektar Therapeutics. Thanks.
NASDAQ:NKTRLong
by QUINNsNextStep
NKTR SHORT 1-Year, Historical supports show more downside.I joined NKTR at the ~12.67 in Jan. 2017. I did not see this historical chart prior to selling early 2018, and then upping the ante throughout 2018, learning more about options contracts as well. Now that I am at a loss of ~$8K, with a cost basis in the mid-40's, I see that even though Bristol-Myers Squibb made a huge investment, the trend should continue downward, barring any medical break-through, reaching supports around $28, $22, and $16. NOT FINANCIAL ADVICE. Let me know what you think. Leave a comment below. Thank you for the consideration.
NASDAQ:NKTRLong
by QUINNsNextStep